Biotech Insider Buying: Seattle Genetics (NASDAQ:SGEN), Cytori Therapeutics Inc. (NASDAQ:CYTX), Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP), OvaScience (NASDAQ:OVAS), TrovaGene Inc (NASDAQ:TROV)

Seattle Genetics Inc (NASDAQ:SGEN) Director Felix Baker bought 546,252 shares of the stock in a transaction dated Monday, June 9th. The shares were purchased at an average cost of $38.16 per share, with a total value of $20,844,976.32. Following the completion of the purchase, the director now directly owns 76,997 shares in the company, valued at approximately $2,938,206. Seattle Genetics, Inc. (NASDAQ:SGEN) net profit margin is 91.70% and weekly performance is 10.19%. On last trading day company shares ended up $39.76. Analysts mean target price for the company is $45.15. Seattle Genetics, Inc. (NASDAQ:SGEN) distance from 50-day simple moving average (SMA50) is 7.30%.

Cytori Therapeutics (NASDAQ:CYTX) Director David Rickey bought 30,000 shares of Cytori Therapeutics stock in a transaction dated Thursday, June 5th. The shares were purchased at an average price of $2.34 per share, with a total value of $70,200.00. Following the completion of the purchase, the director now directly owns 15,819 shares of the company’s stock, valued at approximately $37,016. Cytori Therapeutics Inc. (USA) (NASDAQ:CYTX) shares advanced 2.47% in last trading session and ended the day on $2.49. Gross Margin is 68.70% and its return on assets is -73.90%. Cytori Therapeutics Inc. (USA) (NASDAQ:CYTX) quarterly performance is -13.84%.

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) Major Shareholder Regals Capital Management Lp bought 2,252shares of Cytori Therapeutics stock in a transaction dated Wednesday, June 6th. The shares were purchased at an average price of $ 4.44 per share, with a total value of $ 9,998.88.Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) shares moved up 6.60% in last trading session and was closed at $9.69, while trading in range of $9.01 – $11.15. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) year to date (YTD) performance is -30.14%.

OvaScience Inc (NASDAQ:OVAS) DirectorRichard Aldrich bought 2,000 shares of TrovaGene Inc stock in a transaction dated Monday, June 9th. The shares were purchased at an average price of $ 2,000 per share, with a total value of $ 15,180.00.OvaScience Inc (NASDAQ:OVAS) ended the last trading day at $8.14. Company weekly volatility is calculated as 5.70% and price to cash ratio as 2.22. OvaScience Inc (NASDAQ:OVAS) showed a positive weekly performance of 12.81%.

TrovaGene Inc (NASDAQ:TROV) CFO Steve Zaniboni bought 6,329 shares of TrovaGene Inc stock in a transaction dated Monday, June 9th. The shares were purchased at an average price of $ 3.95 per share, with a total value of $ 24,999.55. TrovaGene Inc (NASDAQ:TROV) weekly performance is -1.04%. On last trading day company shares ended up $3.80. Analysts mean target price for the company is $9.50. TrovaGene Inc (NASDAQ:TROV) distance from 50-day simple moving average (SMA50) is -19.52%.